HDAC1/2–BCL11A Inhibitor Composition for TNBC Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for triple-negative breast cancer (TNBC) are ineffective due to its complex and dynamic nature, making it refractory to conventional anticancer agents, and there is a need for a method to transdifferentiate TNBC into a subtype that responds to conventional therapies.
Innovation Solution
A pharmaceutical composition comprising BCL11A and HDAC1/2 inhibitors is used to inhibit these targets, reprogramming TNBC cells to express ERα, thereby making them sensitive to tamoxifen and other anti-ERα therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticancer agents are used to treat triple-negative breast cancer, then treatment is administered, but the cancer remains refractory and shows poor response
Solution Approach 1:
The patent changes the molecular parameters of TNBC cells by inhibiting HDAC1/2 and BCL11A, which reprograms the cells to express ERα and switch from a refractory state to a responsive state for conventional anticancer agents. This parameter change transforms the fundamental characteristics of the cancer cells to improve drug response.
Solution Approach 2:
The patent uses HDAC1/2 and BCL11A as intermediary targets that mediate the transition between resistant and sensitive states. By inhibiting these intermediary proteins, the cancer cells are forced to reprogram their molecular profile, making them susceptible to conventional therapies that would otherwise be ineffective.
2Reliability
If HDAC1/2 and BCL11A are inhibited to transdifferentiate TNBC, then ERα expression is induced and sensitivity to tamoxifen is enhanced, but the treatment protocol becomes more complex
Solution Approach 1:
The patent applies preliminary action by first inhibiting HDAC1/2 and BCL11A to reprogram TNBC cells before administering conventional anti-ERα therapy. This preliminary reprogramming step prepares the cancer cells to respond effectively to subsequent treatment, creating a sequential approach that improves overall therapy efficacy.
Solution Approach 2:
The patent combines multiple therapeutic components (HDAC1/2 inhibitors, BCL11A inhibitors, and anti-ERα agents) into a composite treatment strategy. This combination approach integrates different mechanisms of action to achieve synergistic effects, transforming refractory TNBC into a responsive condition.
3Manufacturing precision
If transdifferentiation of TNBC into luminal A-type is achieved, then personalized medicine and improved survival are enabled, but the molecular mechanism becomes more complex
Solution Approach 1:
The patent extracts and targets specific molecular drivers (HDAC1/2 and BCL11A) that are responsible for maintaining the resistant state in TNBC. By isolating and inhibiting these specific proteins, the complex molecular mechanism is simplified into actionable therapeutic targets, enabling precise control over the transdifferentiation process.
Solution Approach 2:
The patent employs feedback mechanisms by monitoring ERα expression and cancer cell response during treatment. This feedback allows for real-time adjustment of therapy to ensure successful transdifferentiation and optimal response to personalized medicine interventions.
Data Source
AI summary
The present invention relates to a pharmaceutical composition for treating or preventing malignant breast cancer and, more particularly, to a composition for transdifferentiation of ER-negative breast cancer to luminal breast cancer, comprising an HDAC1/2 inhibitor and a BCL11A inhibitor as active ingredients, and use of the composition. According to the present invention, when target genes of the present invention are inhibited, BLT is induced so that basal-like or triplet-negative breast cancer is transdifferentiated to luminal A subtype breast cancer which is responsive to anticancer therapy, that is, being curable by hormone therapy. Accordingly, an effective and novel drug treatment that has not been conventionally attempted may be provided, thereby not only increasing the survival rate of patients through targeted therapy by realizing personalized medicine, but also contributing to an improvement in the quality of life that results from unnecessary anticancer drug therapy.